Regulatory intelligence helps pharmacovigilance teams understand relevant developments and decide what action is needed. These questions explain how monitoring, interpretation and implementation fit together across products, markets and organisational functions.
Regulatory news provides awareness of developments. Regulatory intelligence adds an assessment of relevance, implications and potential actions for a defined organisation or activity.
A useful service connects the update to the products, markets and processes in scope. Qinecsa’s Regulatory Intelligence service focuses on translating developments into practical insight for pharmacovigilance teams.
Coverage should reflect where your organisation has relevant activities and responsibilities, as well as planned expansion where agreed. It should be defined explicitly rather than assumed from a general description of global support.
Confirm the authorities, topics, languages and product categories included in the engagement. Review this scope when the portfolio or operating model changes.
An update may affect one product category, stage of development or type of activity without applying equally to others. Context helps determine whether the organisation needs to act and which teams should be involved.
Providing accurate information about the portfolio and responsibilities allows a more focused assessment. It also reduces the time spent reviewing updates that are outside scope.
Central monitoring can provide a coordinated view of relevant developments, while local expertise helps assess country-specific context and implementation. The process should identify where local confirmation is needed.
Clear communication between central and regional teams helps prevent inconsistent assumptions. Decisions and local variations should be recorded so that the organisation can understand how the overall position was reached.
Yes, if these are included in the agreed scope. Monitoring consultations and emerging developments can support planning and identify issues that may need specialist attention.
Their status should remain clear. An anticipated change is not the same as a final requirement, and the organisation should track whether the proposal is amended, adopted or withdrawn.
Agree the format, frequency and content of outputs before work begins. Depending on scope, these may include update summaries, applicability assessments, impact reviews or recommended actions.
Clarify whether the provider is responsible for identifying developments, advising on implications or supporting implementation. These are connected activities, but they involve different deliverables and internal commitments.
Implementation ownership should sit with the relevant accountable function or process owner under the organisation’s governance arrangements. A provider may support the work, but responsibilities need to be explicitly agreed.
Where ownership is fragmented, Pharmacovigilance Management Consulting can help clarify decision-making, escalation and coordination between affected teams.
Yes. A defined review can help identify relevant pharmacovigilance considerations and areas requiring further local assessment before expansion.
This insight can inform the wider Pharmacovigilance Consulting plan, including operating model and capability needs. The scope should identify the intended activities and timing so that the review addresses the organisation’s actual plans.
An assessed update may change what staff need to know or do. The impact assessment should therefore consider whether training materials, role guidance or practical exercises need revision.
Pharmacovigilance Training can support this translation into role-specific learning. The aim is to explain the operational consequence of the change, rather than simply circulate the source document.
Assess the implications promptly, establish what action is needed and escalate through the appropriate internal process. Record the circumstances and any immediate measures.
Then investigate why the development was missed or delayed. The cause may involve monitoring coverage, review frequency, unclear ownership or slow internal assessment. Use the findings to improve the process and reduce recurrence.
Strengthen your approach to regulatory change
Explore Qinecsa’s Regulatory Intelligence service to discuss monitoring and assessment aligned with your pharmacovigilance responsibilities.